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Abstract
Protein	folding	homeostasis	in	the	endoplasmic	reticulum	(ER)	is	defended	by	an	
unfolded	 protein	 response	 (UPR)	 that	 matches	 ER	 chaperone	 capacity	 to	 the	
burden	of	unfolded	proteins.	As	levels	of	unfolded	proteins	decline,	a	metazoan-
specific	 FIC-domain	 containing	 ER-localized	 enzyme,	 FICD	 (HYPE),	 rapidly	
inactivates	the	major	ER	chaperone	BiP	by	AMPylating T518.	Here	we	show	that	
the	single	catalytic	domain	of	FICD can	also	release	the	attached	AMP,	restoring	
functionality	 to	 BiP.	 Consistent	 with	 a	 role	 for	 endogenous	 FICD	 in	de-
AMPylating	 BiP,	 FICD
-/-
hamster cells	 are	 hypersensitive	 to	 introduction	 of	 a	
constitutively	 AMPylating,	 de-AMPylation	 defective	 mutant	 FICD.	 These
opposing	 activities	 hinge	 on	 a	 regulatory	 residue,	 E234,	 whose	 default	 state	
renders	 FICD	 a	 constitutive	 de-AMPylase	 in	 vitro.	 The	 location	 of	 E234	 on	 a	
conserved	 regulatory	 helix	 and	 the	 mutually	 antagonistic	 activities	 of	 FICD	 in	
vivo,	 suggest	 a mechanism	whereby	 fluctuating	 unfolded	 protein	 load	 actively	
switches	FICD	from	a	de-AMPylase	to	an	AMPylase.
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Introduction
The	balance	of	chaperones	and	unfolded	proteins in	the	endoplasmic	reticulum	
(ER) is	important	to the	functionality	and	health	of	all	secretory	cells	and	affects
the	outcome	of	diverse	protein	misfolding and	aging-related	diseases	
1,2
.	
Conserved	transcriptional	and	translational	mechanisms, operative	on	a	
timescale	of	hours, match ER	folding	capacity	to	client	protein	abundance	in	all	
eukaryotes
3
. In	metazoans	this	unfolded	protein	response	(UPR)	is	
complemented	by	processes	that	rapidly	inactivate	and	reactivate	the	ER-
localized	Hsp70	chaperone	BiP	to	match	fluctuating	levels	of	unfolded	proteins	
during	the	inherent	delay	of	the	UPR.
Two	processes	are	known	to	contribute	to	this short-term	post-transcriptional	
buffering.	Firstly,	client	protein	binding	is	in	competition	with	rapid	self-binding	
of	BiP	to	form	oligomers	that	serve	as	a	pool	of	recruitable	inactive	chaperone	
4-6
.	
Secondly, an	enzymatically-mediated	inactivating	covalent	modification	of	BiP,	
which	is	conspicuous	when	unfolded	proteins	are	scarce
7,8
	functions	alongside	
mass-action	mediated	oligomerization	to	match	BiP	activity	to	client	protein	
load.	Long	believed	to	be	ADP-ribosylation
4,9
,	this	modification	is	now	known	to
be	AMPylation
10-12
;	the	covalent	attachment	of	adenosine	monophosphate
(AMP),	via	a	phosphodiester	bond	to	the	hydroxyl	side	chain of	a	residue	in	the	
target	protein	(also	known	as	adenylylation)
13
.	
The	ER-localized	FIC-	(filamentation	induced	by	cyclic	AMP)	domain containing	
protein,	FICD	(HYPE)
14
,	uses	ATP	to	AMPylate	BiP	both	in	vitro	and	in	vivo	
10-
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12,15
.	In	cultured	mammalian	cells,	deletion	of	the	FICD	gene	abolishes	all	
evidence	for	BiP	modification,	which	is	otherwise	observed	at	high	
stoichiometry	on	threonine	518.	AMPylated	BiP	(BiP
T518-AMP
)	is	only	weakly
stimulated	by	J-domain	proteins	and	the	modified	chaperone	is	locked	in	a	
relatively	inert	state	
12
.	Like	other	FIC	enzymes	FICD’s	AMPylation	activity	is	
intrinsically	repressed	by	the	intra-molecular	engagement	of	regulatory	residue,	
glutamate	234,	in	FICD’s	active	site	
16,17
.	However,	enforced	expression	of	a	
constitutive	AMPylating	FICD	mutant (that	bypasses	the	aforementioned	
intrinsic	repressive	mechanism)	results	in	high	levels	of	ER	stress	–	most	likely	a	
consequence	of	BiP	inactivation.	These	genetic	and	biochemical	findings	point	to	
FICD	as	being	both	necessary	and	sufficient	for	BiP AMPylation	observed	when	
the	burden	of	unfolded	ER	proteins	is	low.
As	unfolded	proteins accumulate,	pre-existing	AMPylated	BiP	is	rapidly	
converted	to	the	active	de-AMPylated	state
6,11,12
,	indicating	that	BiP	AMPylation	
is	a	reversible	modification	that	contributes	to	the	balance	between	clients	and	
chaperone	in	the	ER.	Regulatory,	de-AMPylating	enzymes	are	known	to	exist:
AMPylated	E.	coli	glutamine synthetase	is	reactivated	by	a	de-AMPylase	encoded	
by	the	N-terminal portion	of	the	same	polypeptide	that	also	encodes	the	
AMPylase	
18,19
,	whereas	in	the	course	of	L.	pneumophilia	infection,	the	AMPylated,	
inactivated	mammalian	host	GTPase	Rab1	is	reactivated	by	a	bacterially-encoded	
de-AMPylating	enzyme,	SidD
20
.	However,	the	counterparts	to	such	enzymes	in	
the	mammalian	ER	are	not	obvious.	This	study	therefore	addresses	the	hitherto	
mysterious	process	by	which	the	phosphodiester	bond	between	AMP	and	the	
hydroxyl	side	chain	of	BiP’s	T518 is broken	and	full	BiP	chaperone	activity	
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restored.
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Results
Overexpression of wildtype FICD cannot restore BiP AMPylation in FICD-deficient 
cells 
AMPylated	BiP,	detected	by	its	characteristic	mobility	on	native-PAGE	or	in	
isoelectric	focusing	gels,	is	readily	observed upon	inhibition	of	protein	synthesis	
in	wildtype	but	not FICD
-/-
	cells (Fig.	1).	However,	overexpression	of	FICD	fails	to	
restore	AMPylation	to	FICD
-/-
	cells.	ER	stress	caused	by	FICD overexpression, is	
unlikely	to	contribute	to	the	lack	of	AMPylated	BiP	as	UPR	signaling	was	not	
activated	in	the	transfected	cells	(see	below).	By	contrast,	the	hyperactive	allele	
FICD
E234G
	readily	restored	AMPylated	BiP	in	FICD
-/-
	cells	[Fig.	1,	lanes	4	&	5 and	
Fig.	2D	in	reference	
12
].	
Unlike	the	transfected	wildtype	FICD,	neither	the	endogenous	FICD,	nor	the	
hyperactive	FICD
E234G
	are	reliably	detectable	in	our	immunoblots.	This	consistent	
finding	reflects	the	low	abundance	of	endogenous	FICD	in	cells	
12
	and	indicates	
that,	though	greatly	overexpressed,	the	wildtype	enzyme	is	unable	to	promote	
AMPylated	BiP	in	FICD
-/-
	cells.	 This	finding	suggested	the	possibility	that	levels	of	
AMPylated BiP	are biphasically-related	to	the	concentration	of	wildtype	FICD	
(but	not	mutant	FICD
E234G
)	and	that	in	addition	to	AMPylating	BiP, wildtype	FICD
also	has	a	role	in	undoing	the	modification; a	function	that dominates	in	
overexpression-prone	trans-rescue	experiments.	
FICD de-AMPylates BiP in vitro 
Speculation	that	failure	to	rescue	AMPylation	reflects	narrow	tolerance	for	FICD	
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dosage	effects	consequent	to	opposing	actions	of	a	single	FICD	enzyme	is	further	
supported	by	observations	that AMPylation	and	de-AMPylation	of	bacterial	
glutamine	synthetase	is	carried	out	by	two	structurally-related	nucleotidylyl	
transferase-like	domains	on	the	same	polypeptide	
19
.	Whilst	the	active	sites	of	
the	aforementioned	Glutamine	Synthetase	Adenylyl	Transferase	(GS-ATase)	are	
not	obviously	related	to	FIC,	the	FIC	fold	also	flexibly	catalyzes	diverse	phospho-
transfer	reactions	
21-23
.	Therefore,	it	seemed	reasonable	to	examine	the	ability	of	
FICD	to	remove	the	AMP	moiety	from	BiP
T518-AMP
.
The	signal	arising	from	the	
32
P-labeled	AMP	of	purified	BiP
T518-AMP
	is	very	stable,	
with	negligible	rates	of	spontaneous	hydrolysis.	However,	addition	of	wildtype	
FICD	led	to	a	time-dependent	decrease	in	radiolabel;	a	feature	shared	neither	by	
the	AMPylation-competent,	hyperactive	FICD
E234G
	nor	by	the	AMPylation-
defective	FICD
H363A
mutant	enzyme	(Fig.	2a).	These	de-AMPylation	reactions	
were	performed	in	the	absence	of	ATP,	precluding	re-AMPylation	by	any	residual	
hyperactive	AMPylating	FICD
E234G
(carried	over	from	the	preceding	AMPylation	
reaction).	The	de-AMPylating	activity	of	wildtype	FICD	was	not	restricted	to	
recombinant	BiP	AMPylated	in	vitro,	as	incubating	lysates	from	cycloheximide-
treated	cells	with	pure	wildtype	FICD	also	led	to	disappearance	of	the	acidic	
AMPylated	form	of	endogenous	BiP,	as	revealed	by	isoelectric	focusing	(Fig.	2b).	
Wildtype	FICD’s	ability	to	catalyze	the	removal	of	AMP	from	BiP
T518-AMP
	was	
confirmed	kinetically	by	following	the	decline	in	the	fluorescence	polarization	
signal	arising	from	BiP	AMPylated	in	vitro with	fluorescent	ATP-FAM as	a	
substrate	(BiP
T518-AMP-FAM
;	Supplementary	Fig.	1).	Importantly,	various	
substitutions	of	FICD
E234
generated	mutant	enzymes	with	widely	different	
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constitutive	AMPylating	activities	(Fig.	2c),	however, all	lacked	detectable	de-
AMPylating	activity	(Fig.	2d),	attesting	to	the	dual	role	of	this	residue	in
regulating	AMPylation
16,17
and	in	affecting	de-AMPylation.
FICD-mediated de-AMPylation products
To	further	characterize	the	FICD-mediated	de-AMPylation	reaction	its	products
were	analyzed.	Comparison	of	the	native	mass	of	unmodified	and	modified	BiP,	
whether	from	FICD-containing	cells	or	from	samples	reacted	with	FICD	and	ATP	
in	vitro,	point	to	the	addition	of	a	single	AMP	moiety	on	any	given	molecule	of	
BiP
12
. Liquid	chromatography	coupled	to	mass	spectrometry	(LC-MS)	of	
peptides	arising	from	a digest	with Arg-C	proteinase	revealed	the	presence	of	a
single	mono-AMPylated	BiP
511-532
	peptide [m/z=	1375.15	(2+)]	
12
that was	absent	
from	samples	of	BiP	that	had	never	been	AMPylated [
12
and	Fig.	3a,	upper	panel].	
Crucially,	this	signal	was	abolished	by	exposure	to	wildtype	FICD	but	not	by	
exposure	to	the	FICD
H363A
	mutant	(Fig.	3a,	middle	and	lower	panels).	The	loss	of	
the	AMPylated	BiP
511-532	
peptide caused	by	FICD	was	matched	by	gain	in	peptides	
with	the	mass	of	the	unmodified	BiP
511-532
[m/z=	1209.62	(2+)]	(Fig.	3b)	pointing
to	the	ability	of	FICD	to	revert	BiP
T518-AMP
	to	its	pre-modified	state.
To	examine	the	fate	of	the	modifying	nucleotide,	protein-free	supernatants	of in	
vitro de-AMPylation	reactions were	examined	by	ion	pair	chromatography.	
Exposure	of	BiP
T518-AMP
	to	wildtype	FICD	led	to	the	emergence	of	a	254	nm	
absorbance	peak	that	overlapped	with	the AMP	marker	(Fig.	3c,	red	trace)	and	
had	indistinguishable	absorption	spectra	by	three-dimensional	analysis
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(Supplementary	Fig.	2).	The	AMP	peak	was	conspicuously	absent	from	reactions	
set	up	with	wildtype	FICD	and	non-AMPylated	BiP	(green	trace)	or	AMPylated	
BiP	and	the	inactive	FICD
H363A
	mutant	(blue	trace).	These	experiments	point	to	a	
role	of	FICD	as	a	phosphodiesterase	that	liberates	AMP	from	AMPylated	BiP.
AMPylated	BiP	is	locked	into	a	low-substrate	affinity,	interdomain-coupled	state	
that	is	relatively	resistant	to	cleavage	by	SubA	
12
,	a	highly	specific	protease	that	
cuts	the	interdomain	linker	of	BiP	
24
.	Native-PAGE	revealed	that	exposure	to	
wildtype	FICD	imparted	sensitivity	to	SubA	on	AMPylated	BiP	(Fig.	3d).	In	the	
absence	of	ATP,	BiP	forms	higher	order	oligomers,	a	process	that	is	impeded	by	
AMPylation	
6
.	Exposure	to	wildtype	FICD	led	to	oligomerization	of	the	largely	
monomeric	AMPylated	form	of	BiP	(Fig.	3e,	compare	lanes	3	&	4).	The	FICD-
mediated	conversion	of	modified	BiP	to	self-binding	unmodified	BiP	was	also	
noticeable	in	native	gels	of	samples	in	presence	of	ATP;	but	only	BiP	dimers	were	
detectable	(Fig.	3d,	compare	lanes	1	&	2).	Thus,	FICD	restored	BiP	to	its	pre-
AMPylated	functional	state.
Enzymatic properties of the FICD de-AMPylase 
FICD-mediated	BiP	AMPylation	is	specific	for	the	intact	full-length	BiP	as	the	
enzyme	fails	to	recognize	T518	when	the	latter	is	presented	in	the	context	of	the	
isolated	substrate-binding	domain	of	BiP	
12
.	To	examine	the	substrate	specificity	
of	FICD’s	phosphodiesterase	activity, the	ability	of	SubA	to	cleave	AMPylated	BiP	
quantitatively	(by prolonged	incubation)	was	exploited.	Exposure	to	FICD	led	to	
the	time-dependent	disappearance	of	the	fluorescent	signal	from	intact	BiP
T518-
AMP-FAM
.	However, FICD	was	unable	to	remove	the	fluorescent	moiety	from	the	
isolated	substrate-binding	domain	of	BiP
T518-AMP-FAM
	(Fig.	4a).	
10
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Kinetic	analysis	of	FICD’s	phosphodiesterase	activity	revealed	the	expected	
enzyme concentration-dependence	of	the	reaction	(Fig.	4b)	and	a	substrate	KM	of	
15.58	±	3.27	µM	and	a	kcat of	9.89	±	0.87	×	10
-3
	sec
-1
	(Fig.	4c).	These	observations	
are	consistent	with	a	specific	but	relatively	slow	de-AMPylase,	sensitive	to	the	
lower	end	of	physiological	fluctuations	predicted	in	the	concentration	of	its	
substrate.	Given	that	BiP	de-AMPylation	proceeds	in	the	absence	of	co-factors	or	
activators,	these	in	vitro	observations	are	consistent	with	the	idea	that	
overexpression	of	wildtype	FICD	exposes	the	ER	to	high	levels	of	a	protein	
whose	default	activity	is	to	de-AMPylation	BiP.
Glu234 switches FICD from AMPylation to de-AMPylation
The	FICD-mediated	BiP	AMPylation/de-AMPylation	cycle	converts	the	co-
substrate	ATP	to	AMP	and	pyrophosphate.	Therefore,	the	production	of	AMP	in	
reactions	assembled	with	BiP,	ATP,	and	combinations	of	FICD	enzymes	was	used	
to	evaluate	the	relative	contribution	of	AMPylation	and	de-AMPylation	to	the	
apparent	inability	of	wildtype	FICD	to	promote	a	pool	of	AMPylated	BiP	(Fig.	1	&	
2c).	No	AMP	was	observed	in	reactions	with	the	de-AMPylation defective	
FICD
E234G
,	consistent	with	stability	of	BiP
T518-AMP
(Fig.	5a,	blue	trace),	however,
substantial	amounts	of	AMP	were	produced	over	time	when	wildtype	FICD	was	
included	alongside	the	hyperactive	mutant	FICD
E234G
	(Fig.	5a,	red	trace	and	Fig.	
5b).	Importantly,	AMP	was	not	produced	in	reactions with	wildtype	FICD	alone	
(Fig.	5a,	black	trace). These	observations	suggest	that	in	the	absence	of	other	yet-
to-be-identified	cellular	components	the	wildtype	enzyme	is	locked	in	an	
AMPylation	incompetent	state,	as	suggested	previously	
16,17
,	although	it	cannot	
be	excluded	that	the	in	vitro	assay	conditions	used	here	selectively	interfere	with	
11
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the	AMPylation	activity	of	the	wildtype	enzyme.	However,	the	wildtype	enzyme	
freely	de-AMPylates	BiP	and	a	single	FICD
E234G
	mutation	flips	the	activity	of	FICD	
from	a	constitutive	de-AMPylase	to	a	pure	AMPylase.
Cellular effects of FICD overexpression 
To	explore	the	role	of	FICD	as	a	BiP	de-AMPylating	enzyme	in	vivo, the	effect	of	
oveexpression	of	the	wildtype	enzyme	on	the	level	of	AMPylated	BiP	was	
analyzed	in	wildtype	CHO-K1	cells.	Exposure	to	cycloheximide	rapidly	led	to	the	
emergence	of	a	strong	signal	of	AMPylated	BiP,	detected	by	its	characteristic	
mobility	on	native-PAGE gels	(‘B’	form)
12
.	This	signal	was	progressively	
attenuated	by	overexpression	of	wildtype	FICD	(Fig.	6a),	consistent	with	de-
AMPylation	of	endogenous	BiP	by	overexpressed FICD.
BiP	potently	represses	UPR	signaling
25,26
, whereas	inactivation	of	BiP,	by	
enforced	AMPylation,	induces	the	UPR
12
.	A	role	for	endogenous	FICD	in	BiP	de-
AMPylation	predicts	more	UPR	activity	in	FICD
-/-
	cells	targeted	with	de-
AMPylation defective,	AMPylation	competent	FICD	derivatives	than	in	similarly-
targeted wildtype	cells.	To	test	this	prediction, the	intensity	of	the	UPR	was	
compared	between	isogenic	wildtype	and	FICD
-/-
UPR	reporter-bearing	CHO-K1
cells	transfected	with	plasmids	encoding	FICD	derivatives.	Expression	of	the	
catalytically-inactive FICD
E234G-H363A
, at similar levels to wildtype FICD, had	no	effect	
on	UPR	signaling,	suggesting an insignificant increase in the unfolded protein load 
by expression of either FICD. Moreover,	de-AMPylation	defective,	AMPylation	
competent	FICD	derivatives	with	mutations	at	E234,	reproducibly	induced	more	
UPR	signaling	in	the	FICD
-/-
	cells	(Fig.	6b	&	Supplementary	Fig.	3).	Conversely,	co-
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expression	of	the	de-AMPylation	competent	wildtype	FICD	attenuated	both
accumulation	of	AMPylated	endogenous	BiP	and	UPR	signaling	induced	by	the	
hyperactive	FICD
E234G
	(Fig.	6c	&	Supplementary	Fig.	4).	Treatment	with	the	ER	
stress-inducing	compounds	tunicamycin	or	thapsigargin,	or	transfection	of	
effector	plasmids expressing	the	Cas9	nuclease	and	single	guide	RNAs	that	target	
the	BiP	gene	promoted	similar	levels	of	UPR	signaling	in	wildtype	and	FICD
-/-
cells	(Supplementary	Fig.	5),	attesting	to	the	selective	sensitization	by	the	FICD
-/-
genotype	towards	effectors	that	inactivate	BiP	by	AMPylation.
BiP	inactivation	has	a	large	fitness	cost	
12,24
.	In	keeping	with	a	role	for	
endogenous	FICD	in	reversing	BiP	inactivation	by	AMPylation,	wildtype	CHO-K1
cells	tolerated stable	expression	of	a	retrovirus	encoding	the	de-AMPylation	
defective, AMPylation-competent	FICD
E234G
	better	than	FICD
-/-
	mutant	cells	(Fig.	
6d).	Together,	these	observations	point	to	a	role	for	endogenous	FICD	in	
reversing	BiP	AMPylation	and	restoring	chaperone	activity	in	cells.
13
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Discussion:
FICD	is	both	necessary	and	sufficient	for	BiP	inactivation	by	AMPylation.	The	
same	enzyme	is	implicated	here	in	removing	this	modification	and	in	BiP	
reactivation.	The	side	chain	of	a	single	residue,	E234	determines	which	of	the	
two	opposing	activities	FICD	will	manifest	in	vitro.	Under	the	conditions	of	our	
assay,	E234	of	wildtype	FICD	blocks	all	BiP	AMPylation	and	renders	the	enzyme	
a	pure de-AMPylase	of	BiP.	Substitutions	at	E234,	abolish	the	BiP-directed	de-
AMPylase	activity	of	FICD	and	unmask,	to	varying	degrees,	its	BiP	AMPylating	
activity.	
FICD’s	E234	lies	at	the	tip	of	a	regulatory	helix	conserved	in	other	FIC	enzymes	
21-
23
	(Fig.	7).	Engagement	of	the	E234	side-chain	in	the	active	site	sterically	and	
electronically,	delocalizes	the	terminal	phosphates	of	the	bound	ATP	to	repress	
AMPylation	
16,17
,	explaining	why,	in	absence	of	other	factors,	wildtype	FICD	is	
inactive	as	an	AMPylase.	However,	the	E234	side-chain	is	flexible,	and	while	
engaged	in	the	active	site	can	either	form	a	salt	bridge	with	FICD’s	R374	or	retain	
its	charged	group	free	to	engage	in	alternative	reactions	(PDB	4uO4	and	4uOU)	
such	as	BiP	de-AMPylation.	
In	vitro,	the	two	forms	of	FICD,	wildtype	and	E234G,	represent	the	extremes	of	
two	opposing	enzymatic	activities.	It	is	likely	that	other	components,	present	in	
the	ER,	specify	which	of	the	two	activities	will	prevail	at	any	time,	thus	sparing	
the	cell	fruitless	cycles	of	ATP-consuming,	BiP	AMPylation	and	de-AMPylation.	It	
is	tempting	to	speculate	that	a	mechanism	exists	for	coupling	the	disposition	of	
14
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the	E234-containing	helix	to	the	burden	of	unfolded	protein	in	the	ER,	such	that	
when	this	burden	is	high	the	E234	side-chain	is	engaged	in	the	active	site	to	
block	AMPylation	and	favor	de-AMPylation. This	appears	to	be	the	default	
conformation	of	pure	FICD,	explaining	its	inability	to	AMPylate	BiP	and	its	
constitutive	BiP	de-AMPylating	activity	in	vitro.	When	the	burden	of	unfolded	
proteins	is	low,	a	conformational	switch	in	FICD	disengages	the	E234	side	chain	
to	promote	AMPylation. This	proposed	short-term	mechanism	for	regulating	
FICD’s	intrinsic	enzymatic	activity	functions	alongside	circuits	known	to	regulate	
the	level	of	the	enzyme,	notably	the	UPR	
10-12
.
The	mechanism	behind	this	in	vivo	switch	remains	to	be	worked	out,	
nonetheless	the	dominance	of	de-AMPylation	over	AMPylation	when	the	
wildtype	enzyme	is	overexpressed,	suggests	that	in	the	ER	too	the	default	state	of	
E234	is	to	engage	the	active	site	and	that	an	active	mechanism,	triggered	in	vivo	
when	the	burden	of	unfolded	proteins	is	low,	pries	E234	from	the	active	site	
converting	wildtype	FICD	to	an	AMPylase.	The	machinery	for	switching	FICD	
from	de-AMPylation	to	AMPylation	is	absent	from	the	in	vitro	assays	conducted	
here	but	the	consequences	of	its	action	are	mimicked	by	the	E234Gmutation,	
which	locks	FICD	in	a	constitutively	AMPylating	mode	(Fig.	7).
The	FIC	domain	is	highly	flexible	in	terms	of	substrate	utilization.	The	bacterial	
FIC	protein	DOC	has	been	observed	both	to	phosphorylate	threonine	382	of	
bacterial	EF-Tu	and	to	dephosphorylate	the	same	residue.	Analysis	of	the	
reaction	products	indicates	that	DOC	mediated	de-phosphorylation	is	achieved	
by	thermodynamically-unfavored	reversal	of	the	phosphorylation	reaction,	re-
generating	a	nucleotide	tri-phosphate	
27
.	By	contrast	the	reaction	products	of	
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FICD-mediated	BiP	de-AMPylation	(unmodified	BiP	and	free	AMP)	argue	against	
simple	mass	action-driven	enzymatic	micro-reversibility	and	suggest	instead	
that	the	active	site	of	FICD	is	exploited	for	two	interdependent,	physiologically-
antagonistic,	chemically-distinct	reactions.
AMPylation	by	FIC-domain	enzymes	employs	a	conserved	HPFx(D/E)GN(G/K)R	
catalytic	loop	to	position	the	attacking	nucleophile	in	close	proximity	to	the	α-
phosphate	of	the	bound	ATP	substrate	
28-30
.	A	co-crystal	structure	of	the	bacterial	
enzyme,	IbpA,	and	its	AMPylated	target,	Cdc42,	indicates	that	the	same	pocket	in	
the	FIC	active	site	can	accommodate	adenosine-phosphate	when	it	is	part	of	the	
ATP	substrate	and	as	part	of	the	AMPylated	Cdc42	product	
28
.	Both	AMPylation	
and	de-AMPylation	by	FICD	require	the	conserved	H363.	Thus,	a	shared	active	
site	residue	contributes	to	two	antagonistic	reactions	initiated	by	different	
attacking	nucleophiles.	
In	AMPylation,	FICD	mediates	a	concerted	deprotonation	and	attack	of	the	T518	
hydroxyl	of	BiP	on	the	α-phosphate	of	the	bound	ATP	substrate	
17,28
.	In	de-
AMPylation	the	hydroxyl	of	a	water	molecule,	likely	activated	by	E234,	may	
attack	the	phosphodiester	bond	of	the	bound	AMP.	It	is	tempting	to	speculate	
that	the	essential	role	of	FICD’s	H363	in	both	reactions	reflects	deprotonation	of	
the	attacking	nucleophile	in	the	AMPylation	reaction	and	protonation	of	the	BiP	
T518	leaving	group	in	the	de-AMPylation	reaction.
Our	analysis	has	been	restricted	to	a	single	FIC	enzyme,	FICD,	and	to	a	single	
substrate,	BiP.	The	role,	if	any,	of	FIC	enzymes,	and	FICD	in	particular,	in	de-
modifying	other	substrates,	remains	to	be	explored.	Nor	is	it	known	if	all	the	
16
V6.6F
functional	consequences	of	FICD	inactivation	can	be	understood	in	the	context	of	
the	enzymes’	role	in	regulating	BiP	activity.	But	in	that	context,	the	findings	
presented	here	are	consistent	with	a	model	whereby	BiP	AMPylation	evolved	as	
an	additional	cellular	buffer	to	fluctuations	in	unfolded	ER	proteins	by	
acquisition	of	a	single	dual-functioning	enzyme	whose	activity	is	switched	in	
vivo	by	positioning	a	conserved	regulatory	residue.	Because	BiP	AMPylation	
responds	directly	to	changes	in	unfolded	protein	load,	without	need	for	gene	
expression	or	protein	synthesis
11
,	the	machinery	for	executing	this	switch	may	
tell	us	something	about	the	most	proximal	steps	in	protein	folding	homeostasis	
in	the	ER.
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Figure Legends:
Figure 1
Introduction	of	wild	type	FICD	into	FICD	deficient	cells	fails	to	restore	BiP	
AMPylation
Immunoblot	 of	 endogenous	 BiP	 resolved	 by	 native	 gel	 electrophoresis	 from	
wildtype	 (wt)	 and	 FICD	deficient	 (-/-)	 CHO-K1	 cells	 transfected	with	 plasmids	
encoding	the	indicated	FICD	derivatives	and	exposed	to	cycloheximide	(CHX)	to	
promote	AMPylated	BiP.	The	major	 species	of	 BiP	 oligomers	 are	 numbered	 by	
order	of	descending	mobility	(I-III).	The	monomeric	AMPylated	‘B’	form	induced	
by	 CHX	 treatment	 and	 the	 ‘A’	 form	 detectable	 in	 untreated	 cells	 are	 marked.	
Immunoblots	of	 the	same	samples	resolved	by	SDS-PAGE	report	on	FICD,	 total	
BiP	 and	 total	 eIF2a	 (which	 also	 serves	 as	 a	 loading	 control)	 and	 the	 acidic	
AMPylated	‘B’	form	of	BiP	resolved	by	isoelectric	focusing	gel	(IEF).	The	asterisk	
indicates	a	band	of	unknown	 identity.	Data	 representative	of	 four	 independent	
experiments	are	shown.
Uncropped	blot	images	are	shown	in	Supplementary	Data	Set	1.
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Figure 2 
FICD de-AMPylates BiP in vitro 
(a)	Autoradiograph	of	an	SDS-PAGE	gel	loaded	with	AMPylated	BiP	(BiP-
32
P-
AMP)	that	had	been	exposed	to	wildtype	of	mutant	FICD	for	the	indicated	time
Wildtype	FICD-dependent	de-AMPylation	of	BiP-
32
P-AMP	was	observed	in	four	
independent	experiments.
(b)	IEF	immunoblots	of	endogenous	BiP	from	lysates	of	untreated	or	
cycloheximide-treated	(CHX) CHO-K1	cells	that	had	been	reacted	in	vitro	with	
the	indicated	FICD	enzymes.
(c)	Autoradiograph	and	Coomassie	stain	(CBB)	of	an	SDS-PAGE	gel	of	BiP	after	
exposure	to	wildtype	or	mutant	versions	of	FICD	in	presence	of	α-
32
P-ATP.	A	
representative	of	three	independent	experiments	is	shown	(n	=	3).
(d)	 Time-dependent	 plot	 of	 fluorescence	 polarization	 (FP)	 of	 BiP	 AMPylated	
with	FAM-labeled	AMP	(BiP
T518-AMP-FAM
)	following	exposure	to	the	indicated	FICD	
proteins.	The	decrease	 in	 the	FP	signal	reflects	release	of	 the	 fluorophore	 from	
BiP.	A	representative	of	five	independent	experiments	is	shown	(n	=	5).
Uncropped	autoradiograph,	gel	and	blot	images	are	shown	in	Supplementary	
Data	Set	1.
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Figure 3 
FICD-mediated	 de-AMPylation	 releases	 AMP	 and	 restores	 BiP	 to	 its	pre-
AMPylation	state	
(a)	LC-MS	spectra	of	 peptides	 from	 an	Arg-C	 digest	 of	 unmodified	BiP	 protein	
(upper	 spectrum)	 or	 AMPylated	 BiP	 (BiP-AMP;	 lower	 two	 spectra)	 incubated	
with	wildtype	or	FICD
H363A
	mutant	enzyme.	The	isotopic	series	of	doubly	charged	
ions	 derived	 from	 the	 AMPylated	 proteolytic	 BiP	 fragment	 (BiP
511-532
;	 1374.15	
m/z,	z	=	2)	are	highlighted	in	grey.	
(b)	 As	 in	 “a”	 but	 showing	 the	 spectra	 of	 the	 unmodified	 BiP
511-532
	 peptides	
(1209.62	m/z,	z	=	2;	isotopic	ensemble	highlighted	in	grey	and	magnified	in	the	
inset).	
(c)	 Absorbance	 traces	 at	 254	 nm	 (A254	 in	 milli	 absorbance	 units)	 of	 ion	 pair	
chromatograms	of	post-proteinaceous	supernatants	from	samples	of	unmodified	
or	in	vitro	AMPylated	BiP	after	incubation	with	wildtype	FICD	or	FICD
H363A
.	The	
elution	profile	of	known	standards	 (ATP,	ADP,	 and	AMP)	 are	 indicated	 in	 grey	
dotted	 lines.	 In	 the	 control	 reaction	 (black	 trace	 on	 the	 left	 panel)	 the	 FICD	
enzyme	was	 added	 to	 BiP-AMP	 followed	 immediately	 by	 deproteination.	FICD-
dependent	 appearance	 of	 an	 A254	 absorbance	 peak	 at	 the	 AMP-specific	 elution	
time	was	observed	in	three	independent	experiments.
(d)	CBB-stained	native-PAGE	gel	of	purified	in	vitro	AMPylated	BiP	that	had	been	
subsequently	 exposed	 to	 the	 indicated	 FICD	 enzymes	 in	 presence	 of	 ATP,	
followed	by	further	exposure	to	SubA	protease	where	 indicated.	The	migration	
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of	the	non-AMPylated	monomeric	‘A’	form	(enriched	in	the	presence	of	ATP),	BiP	
dimers	 (II),	 the	 AMPylated	 ‘B’	 form,	 and	 the	 nucleotide	 binding	 domain	 SubA	
cleavage	 product	 (CP)	 are	 noted.	 A	 representative	 result	 of	 three	 independent	
experiments	is	shown.
(e)	As	in	“d”,	non-AMPylated	and	AMPylated	BiP,	resolved	by	native-PAGE	but	in	
the	absence	of	ATP.	A	representative	of	three	independent	experiments	is	shown.
Uncropped	gel	images	are	shown	in	Supplementary	Data	Set	1.
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Figure 4 
Enzymatic	properties	of	the	FICD	de-AMPylase	
(a)	Fluorograph	and	Coomassie	 stain	of	 intact	 or	 SubA	 cleaved	BiP	AMPylated	
with	 FAM-labeled	 AMP	 (BiP
T518-AMP-FAM
)	 and	 exposed	 to	 wildtype	 FICD	 for	 the	
indicated	time	before	SDS-PAGE.	The	location	of	full-length	BiP	(FL),	the	cleaved	
fluorescent	substrate-binding	(SBD), non-fluorescent	nucleotide	binding	domain	
fragment	(NBD),	FICD	and	SubA	are	noted.	The	asterisk	marks	a	high	molecular	
weight	fluorescent	 species	distinct	 from	 full-length	BiP
AMP-FAM
	 (FL)	 that	 is	not	a	
substrate	 for	 FICD-mediated	 de-AMPylation.	 A	 representative	 of	 two	
independent	experiments	is	shown.
(b)	 Time-dependent	 plot	 of	 fluorescence	 polarization	 (FP)	 measurement	 of	
BiP
T518-AMP-FAM
	 (80	 nM)	 exposed	 to	 increasing	 concentrations	 of	 wildtype	 FICD	
(0.125	to	4	µM)	as	indicated.	A	representative	of	four	independent	experiments	
is	shown.
(c)	Plot	of	 the	relation	between	 initial	substrate	concentration	[BiP
T518-AMP
]i	and	
the	initial	velocity	of	FICD-mediated	de-AMPylation	derived	from	change	in	FP	of	
BiP
T518-AMP-FAM
	 (introduced	 as	 a	 tracer).	 Data	 points	 from	 three	 independent	
experiments and	the	non-linear	fit	curve	are	shown	(KM	=	15.58	µM	±	SD	3.27	µM	
and	kcat	=	9.89	×	10
-3
	sec
-1
	±	SD	0.87	×	10
-3
	sec
-1
).
Uncropped	gel	images	are	shown	in	Supplementary	Data	Set	1.
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Figure 5
Engagement	of	E234	in	the	active	site	switches	FICD	from	AMPylation	to	de-
AMPylation
(a)	Absorbance	traces	of	the	AMP-containing	region	of	ion	pair	chromatograms	
of	 post-proteinaceous	 supernatants	 from	 samples	 derived	 from	 enzymatic	
reactions	incorporating	the	indicated	components.	In	the	control	reaction	(trace	
4,	green)	ATP	was	added	followed	immediately	by	deproteination.	Trace	5	and	6	
are	 of	 identical	 samples	 with	 the	 addition	 of	 AMP	 to	 trace	 6	 before	
chromatography	(orange).	Note	that	the	appearance	of	an	A254	absorbance	peak	
at	 the	 AMP-specific	 elution	 time	 is	 restricted	 to	 the	 reaction	 containing	 both	
FICD
E234G
	and	wildtype	FICD	and	was	observed	in	four	independent	experiments.	
(b)	Absorbance	traces	(as	above)	of	post-proteinaceous	supernatants	from	a	
time	course	of	the	enzymatic	reactions	containing	the	indicated	components.	
Trace	1	(grey	line)	is	the	elution	profile	of	an	AMP	standard.	A	reaction	without	
BiP	(trace	2,	black	line)	serves	as	a	control.
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Figure 6
FICD	counteracts	BiP	AMPylation	in	cells
(a)	 Immunoblot	 of	 endogenous	 BiP	 from	 CHO-K1	 cells	 transfected	 with	 the	
indicated	 amount	 of	 plasmid	 DNA	 encoding	 wildtype	 FICD	 and	 exposed	 to	
cycloheximide	(CHX)	resolved	by	native-PAGE.	The	AMPylated	‘B’	form	of	BiP	is	
indicated	(as	are	the	other	major	species,	see	Fig.	1	legend).	Immunoblots	of	the	
same	samples	 resolved	by	SDS-PAGE	report	on	FICD,	 total	BiP	 and	 total	 eIF2α
(which	 also	 serves	 as	 a	 loading	 control).	 The	 asterisk	 indicates	 a	 background
band.	Data	representative	of	three	independent	experiments	are	shown.
(b)	Activity	of	 an	 integrated	CHOP::GFP	UPR	 reporter	 in	 isogenic	wildtype	 and	
FICD-deficient	CHO-K1	cells	 following	 transfection	with	 plasmids	 encoding	 the	
indicated	FICD	derivatives	and	an	mCherry	transfection	marker).	Shown	are	the	
median	values	±	SD	of	 the	GFP	 fluorescent	 signal	of	 the	mCherry-positive	 cells	
from	 three	 independent	 experiments	 (fold	 change	 relative	 to	 wildtype	 cells	
transfected	with	control	plasmid	DNA	encoding	mCherry	only).
(c)	As	in	“b”,	but	cells	were	co-transfected	with	the	 indicated	pairs	of	plasmids.	
Data	from	three	independent	experiments	are	shown.
(d)	Bar	diagram	of	puromycin-resistant	colonies	of	wildtype	and	FICD-deficient	
CHO-K1	 cells	 transduced	 with	 a	 puromycin	 resistance	 marked	 retrovirus
expressing	 a	 catalytically	 inactive	 FICD
E234G-H363A
	 or	 de-AMPylation	
defective/AMPylation	 active	 FICD
E234G
.	 Shown	 are	 the	mean	 values	 ±	 SD	 of	 the	
number	of	colonies	per	plate	from	three	replicates.	Below	is	a	photograph	of	the	
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crystal	violet	stained	colonies	from	the	samples	described	above.
Uncropped	blot	images	are	shown	in	Supplementary	Data	Set	1.
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Figure 7
A	 hypothetical	 model	 depicting	 regulation	 of	 the	 FICD-mediated	 BiP	
AMPylation	and	de-AMPylation	cycle	by	the	disposition	of	E234
A	 cellular	 mechanism	 responsive	 to	 the	 changes	 in	 unfolded	 protein	 load	 is	
hypothesized	to	switch	FICD’s	function	by	altering	the	position	of	E234.
When	 unfolded	 proteins	 are	 scarce,	 active	 disengagement	 of	 FICD’s	 E234	
promotes	 the	 AMPylation-competent	 alignment	 of	 T518	 of	 BiP,	 ATP	 and	 key	
residues	 from	 the	 active	 site	 (H363	 and	 R374)	
16,17
,	 inactivating	 BiP.	 When	
unfolded	 proteins	 are	 abundant	 FICD	 returns	 to	 its	 default	 state.	 The	 engaged
E234	of	FICD	coordinates	a	water	molecule	 to	attack	 the	phosphodiester	bond	
between	 AMP	 and	 T518	 of	 BiP.	 The	 essential	 role	 of	 FICD’s	 H363	 in	de-
AMPylation	is	plausibly	attributed	to	protonation	of	the	BiP	T518	leaving	group.	
De-AMPylation	 returns	BiP	 to	 the	chaperone	cycle.	The	 bold	 arrows	 indicate	 a	
hypothesized	 movement	 of	 the	 regulatory	 α-helix	 harboring	 E234	 to	 switch	
FICD’s	catalytic	activities	and	the	 light	arrows	 indicate	the	hypothetical	 flow	of	
electrons	according	to	the	proposed	catalytic	mechanism.
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Methods
Cell	lines
All cells were grown on tissue culture dishes or multi-well plates (Corning) at 37°C 
and 5% CO2. CHO-K1 cells (ATCC CCL-61) were phenotypically validated as proline 
auxotrophs and their Cricitulus griseus origin was confirmed by genomic sequencing. 
The cells were cultured in Nutrient mixture F-12 Ham (Sigma) supplemented with 
10% (v/v) serum (FetalClone II; HyClone), 1 x Penicillin-Streptomycin (Sigma) and 2 
mM L-glutamine (Sigma). The CHO-K1 FICD-/- cell lines used in this study were 
described previously 12.
HEK293T cells (ATCC CRL-3216) were cultured in Dulbecco's Modified Eagle's 
Medium (Sigma) supplemented as described above.
Cell lines were subjected to random testing for mycoplasma contamination using the 
MycoAlert Mycoplasma Detection Kit (Lonza). Experiments were performed at cell 
densities of 60-90% confluence. Cells were treated with drugs at the following final 
concentrations: 100 µg/ml cycloheximide (Sigma), 2.5 µg/ml tunicamycin (Melford), 
0.5 µM thapsigargin (Calbiochem), and 6-8 µg/ml puromycin (Calbiochem). All drugs 
were first diluted in fresh, pre-warmed medium and then applied to the cells by 
medium exchange.
Detailed information on flow cytometry analysis procedures, and production of VSV-
G retroviral virus in HEK293T cells and infection of CHO-K1 cells can be found in 
Supplementary Note.
Mammalian	cell	lysates
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Cell lysis was performed as described in 6 with modifications. In brief, mammalian cells 
were cultured on 10 cm dishes and treated as indicated and/or transfected using 
Lipofectamine LTX with 5 µg plasmid DNA unless	 indicated	 otherwise,	 and	
allowed	to	grow	for	24	hours. Before lysis the dishes were placed on ice, washed 
with ice-cold PBS, and cells were detached in PBS containing 1 mM EDTA using a 
cell scraper. The cells were sedimented for 5 minutes at 370 g at 4°C and lysed in HG 
lysis buffer [20 mM HEPES-KOH pH 7.4, 150 mM NaCl, 2 mM MgCl2, 10 mM D-
glucose, 10% (v/v) glycerol, 1% (v/v) Triton X-100] containing protease inhibitors (2 
mM PMSF, 4 µg/ml pepstatin, 4 µg/ml leupeptin, 8 µg/ml aprotinin) with 100 U/ml 
hexokinase (from Saccharomyces cerevisiae Type F-300; Sigma) for 10 minutes on 
ice. The lysates were cleared for 10 minutes at 21,000 g at 4°C. BIO-RAD protein 
assay reagent (BioRad) was used to determine the protein concentrations of lysates 
followed by normalization. For analysis by SDS-PAGE, SDS sample buffer was added 
to the lysates and proteins were denatured by heating for 10 minutes at 70°C before 
separation on 12.5% SDS polyacrylamide gels. To detect endogenous BiP by native-
PAGE the lysate samples were loaded immediately on native gels (see below). 
Plasmid construction
Supplementary Table 1 lists the plasmids used in this study. Standard PCR and 
molecular cloning methods were used to generate DNA constructs and point mutations 
were introduced by PCR-based site-directed mutagenesis.
Protein purification
N-terminally hexahistidine- (His6-) tagged wildtype and mutant Chinese hamster BiP 
proteins were expressed in M15 E. coli cells (Qiagen). The bacterial cultures were 
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grown at 37°C to an optical density (OD600 nm) of 0.8 in LB medium supplemented with 
50 µg/ml kanamycin and 100 µg/ml ampicillin and expression of recombinant protein 
was induced by the addition of 1 mM isopropylthio β-D-1-galactopyranoside (IPTG). 
The cells were further incubated at 37°C for 6 hours, harvested by centrifugation, and 
lysed with a high-pressure homogenizer (EmulsiFlex-C3, Avestin) in buffer A [50 mM 
Tris-HCl pH 7.5, 500 mM NaCl, 1 mM MgCl2, 0.2% (v/v) Triton X-100, 10% (v/v) 
glycerol, 20 mM imidazole] containing protease inhibitors [2 mM 
phenylmethylsulphonyl fluoride (PMSF), 4 µg/ml pepstatin, 4 µg/ml leupeptin, 8 µg/ml 
aprotinin] and 0.1 mg/ml DNaseI. The obtained lysates were cleared by centrifugation 
for 30 minutes at 25,000 g and incubated with 1 ml Ni-NTA agarose (Qiagen) per 1 l 
of expression culture for 2 hours at 4°C. The matrix was transferred to a column and 
washed five times with 20 bed volumes of buffer A containing 5 mM β-
mercaptoethanol and supplemented sequentially with (i) 30 mM imidazole, (ii) 1% 
(v/v) Triton X-100, (iii) 1 M NaCl, (iv) 5 mM Mg2+-ATP, or (v) 0.5 M Tris-HCl pH 
7.5. Bound BiP proteins were eluted in buffer B [50 mM HEPES-KOH pH 7.5, 300 
mM NaCl, 10% (v/v) glycerol, 5 mM β-mercaptoethanol, 250 mM imidazole] and 
dialyzed against HKM buffer [50 mM HEPES-KOH pH 7.4, 150 mM KCl, 10 mM 
MgCl2]. The proteins were concentrated using centrifugal filters (Amicon Ultra, 30 
kDa MWCO; Merck Millipore), snap-frozen in liquid nitrogen, and stored at -80°C. 
Bacterial expression and purification of N-terminally GST-tagged wildtype and mutant 
FICD proteins was performed according to 12 with modifications. The FICD-encoding 
DNA constructs were transformed into C3013 BL21 T7 Express lysY/Iq E. coli cells 
(New England BioLabs) and cultures of single clones were grown at 37°C in LB 
medium containing 100 µg/ml ampicillin. At an OD600 nm of 0.8 the cultures were 
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shifted to 20°C and expression was induced with 0.5 mM IPTG. After incubation for 
16 hours the cells were harvested and lysed as described above in lysis buffer [50 mM 
Tris-HCl pH 7.5, 500 mM NaCl, 1 mM MgCl2, 2 mM dithiothreitol (DTT), 0.2% (v/v) 
Triton X-100, 10% (v/v) glycerol] containing protease inhibitors and DNaseI. The 
lysates were cleared by centrifugation for 30 minutes at 25,000 g and incubated with 
0.7 ml Glutathione Sepharose 4B (GE Healthcare) per 1 l of expression culture for 2 
hours at 4°C. The beads were washed with 20 ml wash buffer C [50 mM Tris-HCl pH 
7.5, 500 mM NaCl, 1 mM DTT, 0.2% (v/v) Triton X-100, 10% (v/v) glycerol] 
containing protease inhibitors, 20 ml wash buffer D [50 mM Tris-HCl pH 7.5, 300 mM 
NaCl, 10 mM MgCl2, 1 mM DTT, 0.1% (v/v) Triton X-100, 10% (v/v) glycerol] 
containing protease inhibitors and 20 ml wash buffer D sequentially supplemented with 
(i) 1% (v/v) Triton X-100, (ii) 1 M NaCl, (iii) 3 mM ATP, or (iv) 0.5 M Tris-HCl pH 
7.5. Bound proteins were eluted in elution buffer [50 mM HEPES-KOH pH 7.4, 100 
mM KCl, 4 mM MgCl2, 1 mM CaCl2, 0.1% (v/v) Triton X-100, 10% (v/v) glycerol, 40 
mM reduced glutathione] and concentrated protein solutions were frozen in liquid 
nitrogen and stored at -80°C. For preparation of wildtype FICD without the GST-tag 
the protein was eluted from glutathione-Sepharose in elution buffer without Triton X-
100 and with 1.5 mM DTT. TEV protease was added in a 100:1 (protein-to-TEV) 
molar ratio and after incubation for 16 hours at 4°C the proteins were passed over a 
size-exclusion chromatography column (Superdex 200 10/300 GL; GE Healthcare) in 
HKMG buffer [50 mM HEPES-KOH pH 7.4, 150 mM KCl, 10 mM MgCl2, 10% 
glycerol]. The FICD protein-containing fractions were pooled, concentrated, and 
frozen in aliquots. 
Purification of in vitro AMPylated BiP proteins
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AMPylated BiP proteins were prepared as described previously 12, with modifications. 
In brief, 20 mg of purified wildtype BiP or substrate-binding deficient BiPV461F mutant 
protein 31 was in vitro AMPylated for 4 hours at 30°C with 0.25 mg bacterially 
expressed FICDE234G in presence of 3 mM ATP in buffer E [25 mM HEPES-KOH pH 
7.4, 100 mM KCl, 10 mM MgCl2, 1 mM CaCl2, 0.1% (v/v) Triton X-100]. 
Afterwards, BiP proteins were bound to 400 µl Ni-NTA agarose affinity matrix for 30 
minutes at 25°C, washed with buffer E, and eluted in buffer E containing 350 mM 
imidazole for 45 minutes at 25°C. The eluate was concentrated and passed over a 
Centri•Pure P25 desalting column (emp BIOTECH) equilibrated in HKMG buffer. The 
protein-containing fractions were pooled, concentrated, frozen in liquid nitrogen, and 
stored at -80°C. BiP was quantitatively AMPylated as judged by the conversion of BiP 
oligomers into the modified monomeric ‘B’ form on a native-PAGE gel. The modified 
BiP proteins were used for in vitro de-AMPylation assays and mass spectrometry 
analysis (see below). Unmodified BiP prepared from a parallel mock AMPylation 
reaction without enzyme served as a control. 
In vitro AMPylation and de-AMPylation assays
Unless stated otherwise in vitro AMPylation and de-AMPylation reactions were 
performed in AMPylation buffer [25 mM HEPES-KOH pH 7.4, 100 mM KCl, 4 mM 
MgCl2, 1 mM CaCl2, 0.1% (v/v) Triton X-100].
Radioactive in vitro AMPylation (Fig. 2c) reactions were set up in a final volume of 
37.5 µl containing 1 µM of ATP hydrolysis-deficient mutant BiP protein (BiPT229A) 32, 
0.1 µM wildtype or mutant FICD proteins, 40 µM ATP, and 0.023 MBq α-32P-ATP 
(EasyTide; Perkin Elmer). The reactions were started by addition of the nucleotides 
and incubated at 25°C. After 3 and 10 minutes of incubation 15 µl were removed from 
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each reaction, respectively, supplemented with 5 µl SDS sample buffer, heated for 5 
minutes at 75°C and loaded on a SDS-PAGE gel. Gels were stained with Coomassie 
and the radioactive signals were detected with a Typhoon Trio imager (GE Healthcare) 
upon overnight exposure of the dried gels to a storage phosphor screen.
For radioactive de-AMPylation experiments (Fig. 2a) BiP was first AMPylated in vitro 
with α-32P-ATP and then re-purified. Therefore, 6 µg of purified BiP was pre-
incubated with 15 µM ATP in a final volume of 20 µl in AMPylation buffer for one 
minute at 25°C before 1.85 MBq α-32P-ATP and 2 µg FICDE234G was added. The 
mixture was incubated for 10 minutes at 25°C and another 12 µg of BiP was added. 
After further incubation for 50 minutes the reaction was diluted with 200 µl of high-
salt AMPylation buffer [25 mM HEPES-KOH pH 7.4, 500 mM KCl, 4 mM MgCl2, 1 
mM CaCl2, 0.1% (v/v) Triton X-100] and 1 mM ATP was added. BiP was then bound 
to 20 µl Ni-NTA agarose beads for 30 minutes at 20°C. The beads were washed with 
500 µl high-salt AMPylation buffer containing 1 mM ATP and three times with high-
salt AMPylation buffer. Bound proteins were eluted in 100 µl AMPylation buffer 
containing 400 mM imidazole (pH 7.4) for 30 minutes at 20°C. The eluate was split in 
two fractions of 50 µl and each fraction was passed through a Sephadex G-50 
MicroSpin column (illustra AutoSeq G-50; GE Healthcare) equilibrated with 
AMPylation buffer, and the recovered proteins were frozen in aliquots until the de-
AMPylation experiment. The de-AMPylation reactions were carried out at 23°C in a 
final volume of 15 µl in AMPylation buffer containing 1.3 µg non-radioactive 
AMPylated wildtype BiP supplemented with trace amounts of radiolabelled 
AMPylated BiP (≈ 0.1 µg). The reactions were started at different time points by 
addition of 0.13 µg wildtype or mutant FICD. At the end of the experiment 5 µl SDS 
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sample buffer were added to each reaction, proteins were denatured for 5 minutes at 
75°C, and 15 µl of each sample were applied to SDS-PAGE. After separation, the 
proteins were stained with Coomassie to confirm equal loading and radioactive signals 
were detected by autoradiography as described above.
The non-radioactive de-AMPylation reactions shown in Fig. 3d contained 1 µg/µl 
purified AMPylated wildtype BiP, 0.1 µg/µl wildtype or mutant FICD, and were 
incubated for 90 minutes at 30°C in a final volume of 25 µl in presence of 3 mM ATP. 
Afterwards, each reaction was divided in two samples, one of which was treated for 10 
minutes with 0.06 µg/µl SubA protease at 25°C, whereas the other remained 
untreated. The samples were then supplemented with native sample buffer and 
analysed immediately by native-PAGE and Coomassie staining (see below). The de-
AMPylation reactions shown in Fig. 3e were performed in HKM buffer and contained 
1 µg/µl purified AMPylated or unmodified wildtype BiP and were incubated without 
or with 0.05 µg/µl wildtype FICD for 30 minutes at 30°C in absence of ATP (to allow 
re-formation of BiP oligomers) before analysis by native-PAGE.
The reactions shown in Fig. 2b contained 3 µg/µl protein from lysates of untreated 
wildtype CHO-K1 cells or cells treated for 3 hours with CHX, and 0.15 µg/µl purified 
wildtype or mutant FICD (see above). The reactions were started by addition of 
purified FICD and incubated at 30°C. After 15 minutes, the reactions were diluted 
1:10 in IEF lysis buffer and analysed by IEF (see below).
Detailed information on Fluorescence polarization assay procedures can be found in 
Supplementary Note.
Mass spectrometry
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For mass spectrometry analysis purified in vitro AMPylated or unmodified wildtype 
BiP (Chinese hamster) at 16 µM was incubated with 0.8 µM wildtype FICD or 
catalytically inactive mutant FICDH363A for 3 hours at 30°C. Afterwards, the proteins 
were denatured with SDS sample buffer, heated for 5 minutes at 75°C, and separated 
by SDS-PAGE. The gels were stained with Coomassie, destained, and the bands at 75 
kDa corresponding to BiP protein were excised. The	proteins	were	then	reduced,	
alkylated,	and	digested	“in-gel”	with	Arg-C	proteinase.	The	obtained	peptides	
were	analyzed	by	LC-MS	using	a	Q	Exactive	mass	spectrometer	(Thermo	Fischer)	
coupled	to	a	RSLC	3000	UHPLC.	The	data	were	processed	with	Proteome	
Discoverer	1.4	using	Sequest	to	search	a	Uniprot	E.	coli	database	(downloaded	
29/04/15,	4377	entries)	with	the	sequence	of	Chinese	hamster	(Cricetulus	
griseus)	BiP	added.	Oxidation	(M)	and	AMPylation	(S/T)	were	set	as	variable	
modifications	and	carbamidomethylation	(C)	as	a	fixed	modification.	FDR	
calculations	were	performed	by	Percolator	and	peptides	were	filtered	to	1%.	
Ion pair chromatography (IPC)
To detect the leaving group of the FICD-mediated de-AMPylation reaction, reversed-
phase IPC was performed (Fig. 3c). Purified in vitro AMPylated or unmodified BiP 
proteins at 65 µM were exposed to wildtype FICD or mutant FICDH363A proteins at 6.5 
µM in HKM buffer in a final volume of 30 µl for 2 hours at 30°C. At the end of the 
incubation time the reactions were stopped by addition of 10 µl of 4 M perchloric acid 
(PCA). As a negative control AMPylated BiP was incubated in parallel for 2 hours 
without enzyme and FICD was added directly before mixing with PCA. After 
incubation for 5 minutes on ice the samples were centrifuged at 21,000 g for 2 minutes 
at 4°C and 32 µl of the supernatants were mixed with 20 µl of 2 M potassium 
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hydroxide (KOH). The pH of the samples was neutralized, the precipitates were 
sedimented by centrifugation for 15 minutes at 21,000 g at 4°C, and the cleared 
supernatant were equilibrated to room temperature before analysis by IPC. For that, 20 
µl of each sample were injected onto a Poroshell 120 EC-C18 HPLC column (3 x 150 
mm, 2.7 µm; Agilent Technologies) connected to a UHPLC Guard column (Agilent 
Technologies). Buffers A [H2O + 10 mM tetrabutylammonium hydroxide (TBAH) + 
10 mM potassium dihydrogen phosphate (KH2PO4)] and B [methanol (CH3OH) + 10 
mM TBAH] were used as a mobile phase. The runs were performed at a constant flow 
rate of 0.4 ml/min at room temperature using the following gradient: 5% to 50% B in 
25 minutes, hold for 2 minutes at 50% B, ramp to 95% B in 0.1 minute, hold for 7 
minutes, 95% to 5% B in 1 minute, hold for 5 minutes at 5% B (re-equlibration to 
basal). Nucleotide absorbance traces at 254 nm (A254 nm) were recorded and plotted 
against elution time. A nucleotide standard was applied in each experiment to 
determine the retention times of ATP, ADP and AMP. 
Coupled AMPylation/de-AMPylation reactions (Fig. 3d and Supplementary Fig. 2) 
contained 20 µM ATP hydrolysis-deficient BiPT229A, 2 µM wildtype FICD, 2 µM 
FICDE234G, and 2 mM ATP in HKM buffer as indicated and were incubated for 3 hours 
at 30°C before deproteination and HPLC analysis as described above. 
Native polyacrylamide gel electrophoresis (native-PAGE)
Non-denaturing native-PAGE was performed as described 6. Briefly, Tris-glycine 
polyacrylamide gels (4.5% stacking gel and a 7.5% separation gel) were used to 
separate purified proteins or proteins from mammalian cell lysates to detect BiP 
oligomers. The separation was performed in running buffer (25 mM Tris, 192 mM 
glycine, pH ~8.8) at 120 V for 2 hours. Afterwards, the proteins were visualized by 
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staining with InstantBlue Coomassie solution (expedeon) or transferred to a 
polyvinylidene difluoride (PVDF) membrane in blotting buffer (48 mM Tris, 39 mM 
glycine; pH ~9.2) supplemented with 0.04 (w/v) SDS for 16 hours at 30 V for 
immunodetection. The membrane was washed for 20 minutes in blotting buffer 
(without SDS) supplemented with 20% (v/v) methanol before blocking. Seven µg of 
purified BiP protein was loaded per lane to detect purified BiP proteins by Coomassie 
staining and volumes of lysates corresponding to 30 µg of total protein were loaded 
per lane to detect endogenous BiP from CHO-K1 cell lysates by immunoblotting.
Immunoblot analysis
After separation by SDS-PAGE or native-PAGE (see above) the proteins were 
transferred onto PVDF membranes. The membranes were blocked with 5% (w/v) 
dried skimmed milk in TBS (25 mM Tris-HCl pH 7.5, 150 mM NaCl) and incubated 
with primary antibodies followed by IRDye fluorescently labeled secondary antibodies 
(LiCor). The membranes were scanned with an Odyssey near-infrared imager (LiCor). 
Primary antibodies and antisera against hamster BiP [chicken anti-BiP; 33], eIF2α
[mouse anti-eIF2α; 34], and FICD [chicken anti-FICD 12] were used.
Isoelectric focusing (IEF)
Analysis of lysates from mammalian cells by IEF was performed as described 
previously 12. Cells were grown in 10 cm dishes to approximately 90% confluence and 
treated with cycloheximide for 3 hours. Afterwards, the cells were washed with ice-
cold TBS, resuspended in 1 ml TBS, sedimented by centrifugation, and lysed in 30 x 
its packed cell pellet volume of IEF lysis buffer [8.8 M urea, 5% (w/v) CHAPS, 1 µM 
sodium pyrophosphate, 2 mM imidodiphosphate, 50 mM DTT, 2% (v/v) Pharmalyte] 
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at room temperature for 5 minutes. The lysates were centrifuged at 21,000 g for 10 
minutes at room temperature and the resulting supernatants were centrifuged again for 
60 minutes. The cleared lysates were passed over a Sephadex G-50 MicroSpin 
columns equilibrated with IEF sample buffer [8 M urea, 5% (w/v) CHAPS, 50 mM 
DTT, 2% (v/v) Pharmalyte (pH 4.5-5.4; GE Healthcare)], and 15 µl loaded on a 
3.75% polyacrylamide gel containing 8.8 M urea, 1.25% (w/v) CHAPS, and 5% (v/v) 
Pharmalyte. The wells were overlaid with 0.5 M urea and 2% (v/v) Pharmalyte 
solution before the run. The anode buffer was 10 mM glutamic acid and the cathode 
buffer was 50 mM histidine. The run was performed as follows: 100 V for 10 minutes, 
250 V for 1 hour, 300 V for 1 hour, 500 V for 30 minutes. The proteins were then 
transferred to a nitrocellulose membrane for 3 hours at 300 mA in blotting buffer [25 
mM Tris-HCl pH 9.2, 190 mM glycine, 0.01% (w/v) SDS, 10% (v/v) methanol] and 
BiP was detected as described above.
Data availability 
The authors declare that the data supporting the findings of this study are available 
within the paper and its supplementary information files. Source data for Fig. 6 and 
supplementary Fig. 5 are provided with the paper online.
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Supplementary Figure 1 
AMPylation with ATP-FAM generates BiP specifically labeled on its substrate binding domain 
(a) SDS-PAGE gel of AMPylated BiP incubated without or with SubA protease. BiP was AMPylated in vitro with FICDE234G in presence 
of a fluorescently labeled ATP derivative (ATP-FAM) and the resulting AMPylated BiP, with a fluorescent AMP attached (BiPT518-AMP-
FAM) was re-purified (as in Fig. 2d). After prolonged treatment without or with SubA (4 hours at 30°C) the samples were denatured and 
applied to SDS-PAGE. The fluorescence signals of the fluorophore in the gel were detected (excitation: 488 nm, emission: 526 nm; 
upper panel) and the proteins were visualized by staining with Coomassie (CBB; lower panel). Uncleaved full-length BiPT518-AMP-FAM 
(FL), the nucleotide binding domain (NBD), the substrate binding domain (SBD), FICD, and SubA are indicated.  
(b) Time-dependent plot of fluorescence polarization (FP) of BiP AMPylated with FAM-labeled AMP (BiPT518-AMP-FAM, from the sample 
shown in “a” above) after incubation without (black line) or with wildtype FICD protein (red line). The decrease in the FP signal reflects 
release of the fluorophore from BiP. 
Uncropped gel images are shown in Supplementary Data Set 1. 
 
 
 
 			 	
Supplementary Figure 2 
Absorbance spectra of ion pair chromatography elution profiles 
 
 
(a) 3D absorbance plots of the nucleotide standard (upper panel) and the ‘BiP-AMP + FICD’ de-AMPylation sample (lower panel) 
shown in Fig. 3c (grey and red traces therein). The elution profiles between 6 and 13 minutes are shown. Note that the absorbance 
characteristics of the AMP standard and the de-AMPylation product (both eluting at ~11.1 minutes) are qualitatively indistinguishable 
with an absorbance maximum at ~260 nm (arrows). 
 (b) Direct comparison of the absorbance spectra at 11.14 minutes of the profiles shown in “a”. 
 
 
 
 
Supplementary Figure 3 
Analysis of FICD overexpression in cells 
 
 
(a) FICD immunoblot of FICD-deficient (-/-) CHO-K1 cells transfected with plasmids encoding the indicated FICD derivatives. The eIF2α 
below serves as a loading control. Note the higher protein levels of the weaker AMPylation active/de-AMPylation defective 
FICDE234V/L/Q/K mutants compared to the AMPylation hyperactive FICDE234G. 
(b) Flow cytometry source data from a representative experiment (one of three) used to generate the plot in Fig. 6b. 
Uncropped blot images are shown in Supplementary Data Set 1. 
 
 
 
 
Supplementary Figure 4 
Analysis of FICD overexpression by flow cytometry and native-PAGE 
 
 
(a) Flow cytometry source data from one of three independent repeats plotted in Fig. 6c. 
(b) Immunoblot of endogenous BiP from wildtype and FICD-deficient (-/-) CHO-K1 cells resolved by native-PAGE. The cells were co-
transfected with the indicated pairs of plasmids as in Fig. 6c and allowed to grow for 36 hours. The AMPylated ‘B’ form of BiP is 
indicated (as are the other major species, see Fig. 1 legend). Immunoblots of the same samples resolved by SDS-PAGE report on 
FICD, total BiP and total eIF2α (which also serves as a loading control). Data representative of two independent experiments are 
shown. 
Note the absence of AMPylated BiP (‘B’ form) in cells co-transfected with wildtype FICD and the de-AMPylation defective/AMPylation 
active FICDE234G. 
Uncropped blot images are shown in Supplementary Data Set 1. 
 
 
 
 
Supplementary Figure 5 
Wildtype and FICD-deficient (-/-) cells respond indistinguishably to unfolded protein stress in the ER 
(a) Flow cytometry analysis of wildtype and FICD-deficient (-/-) CHO-K1 CHOP::GFP UPR reporter cells treated with the UPR-inducing 
compounds, tunicamycin (2.5 µg/ml) or thapsigargin (0.5 µM), for 16 hours before analysis. Note the equal accumulation of 
CHOP::GFP-positive cells in tunicamycin- or thapsigargin-treated wildtype and FICD-/- cells. 
(b) Plot of the median values ± SD of the GFP fluorescent signal of the samples described in “a” from three independent experiments 
(fold change relative to untreated wildtype cells). 
(c) Flow cytometry analysis of wildtype and FICD-deficient (-/-) CHO-K1 CHOP::GFP UPR reporter cells transiently transfected with 
plasmids encoding the Cas9 nuclease and single guide RNAs targeting hamster BiP. Note the similar levels of UPR signaling in 
wildtype and FICD-/- cells. 
(d) Plot of the median values ± SD of the CHOP::GFP fluorescent signal in the transfected subpopulation of the cells shown in “c” from 
three independent experiments. Transfected cells were identified by co-expression of a mCherry marker (not shown) carried by the 
Cas9 plasmid (fold change relative to wildtype cells transfected with plasmid DNA encoding Cas9 and mCherry only). 
 	
Supplementary	Note	
Flow	cytometry	
FICD (wildtype vs. mutants) overexpression-dependent induction of unfolded protein 
response signalling was analyzed by transient transfection of wildtype and FICD-/- 
CHOP::GFP CHO-K1 UPR reporter cell lines with plasmid DNA encoding the FICD 
protein and mCherry as a transfection marker, using Lipofectamine LTX as described 
previously 1; 2 µg DNA were used in Fig. 6b and 1 µg each plasmid were used in Fig. 
6c. Thirty-six hours after transfection cells were washed with PBS and collected in 
PBS containing 4 mM EDTA, and single cell fluorescent signals (20,000/sample) 
were analyzed by dual-channel flow cytometry with an LSRFortessa cell analyzer 
(BD Biosciences). GFP and mCherry fluorescence was detected with excitation laser 
488 nm, filter 530/30, and excitation laser 561, filter 610/20, respectively. Data were 
processed using FlowJo and median reporter (in Q1 and Q2 in Fig. 6b & c) analysis 
was performed using Prism. 
The sensitivity to UPR induction in wildtype and FICD-deficient CHO-K1 
CHOP::GFP UPR reporter cell lines was analyzed by treating cells with UPR-
inducing compounds, tunicamycin or thapsigargin, for 16 hours before analysis, or 
transient transfection with 2 µg plasmid DNA encoding the Cas9 nuclease and single 
guide RNAs targeting hamster BiP. The two single guide RNA sequences (plasmids 
UK1857 and UK1858; Supplementary Table 1) for targeting the second exon of 
Cricetulus griseus (Chinese hamster) BiP (HSPA5) were selected from the CRISPy 
database [URL: http://staff.biosustain.dtu.dk/laeb/crispy/, 2] and duplex DNA 
oligonucleotides of the sequences were inserted into the pSpCas9(BB)-2A-
mCherry_V2 plasmid (plasmid UK1610; Supplementary Table 1) as described 3. Four 
days after transfection cells were analysed by flow cytometry as described above. 
Production	of	VSV-G	retroviral	virus	in	HEK293T	cells	and	infection	of	CHO-K1	cells	
The effect of expression of de-AMPylation-defective/AMPylation-active FICDE234G 
on mammalian cell fitness was analyzed by colony outgrowth of wildtype and FICD-/- 
CHO-K1 cell lines targeted with puromycin-resistant retrovirus expressing FICDE234G. 
For that HEK293T cells were split onto 6 cm dishes 24 hours prior to co-transfection 
of pBABE Puro plasmids 4 encoding FICDE234G or inactive FICDE234G-H363A (plasmids 
UK1852 and UK1853, respectively; Supplementary Table 1) with VSV-G retroviral 
packaging vectors, using TransIT-293 Transfection Reagent (Mirus) according to the 
manufacturer’s instructions. Sixteen hours after transfection, medium was changed to 
medium supplemented with 1% BSA (Sigma). Retroviral infections were performed 
following a 24 hours incubation by diluting 0.45 µm filter-sterilized cell culture 
supernatants at a 1:2 ratio into CHO-K1 cells medium supplemented with 10 µg/ml 
polybrene (4 ml final volume) and adding this preparation to wildtype or FICD-/- 
CHO-K1 cells (3 x 105 cells seeded onto 6 cm dishes 24 hour prior to infection). 
Infections proceeded for 8 hours, after which viral supernatant was replaced with 
fresh medium. Forty-eight hours later cells were split into medium supplemented with 
6 µg/ml puromycin, and 24 hours afterwards this was changed to medium 
supplemented with 8 µg/ml puromycin. The medium was changed every third day 
until puromycin-resistant colonies were visible. Colonies remaining on the dishes 9 
days after infection were visualized by crystal violet stain and counted. 
Fluorescence	polarization	assay	
The probe to measure the kinetics of FICD-mediated de-AMPylation by fluorescence 
polarization (FP) assays was generated as follows: Purified active FICDE234G at 10 
µM was pre-incubated with 2 mM 5-FAM-labeled N6-(6-Amino)hexyl-adenosine-5’-
triphosphate (ATP-FAM; Jena Bioscience) in HKMG buffer for 5 minutes at 25°C 
before BiPV461F protein at 10 µM was added to yield a final reaction volume of 50 µl. 
The substrate binding- and oligomerisation-deficient BiPV461F mutant was used to 
avoid effects caused by BiP oligomerisation on fluorescence polarization 
measurements. The AMPylation reaction was allowed to proceed for 2 hours at 25°C. 
BiP protein was then bound to Ni-NTA agarose beads in presence of 0.01% (v/v) 
Triton X-100 and after several wash steps in the same buffer proteins were eluted in 
HKMG containing 250 mM imidazole. The eluted proteins were passed over a 
desalting column equilibrated in HKMG and aliquots were frozen in liquid nitrogen 
and stored at -80°C. 
To confirm covalent modification of BiPV461F with AMP-FAM the eluted proteins 
were incubated without or with 60 ng/µl SubA protease for an elongated period of 
time (4 hours) in AMPylation buffer at 30˚C. The proteins were then denatured in 
SDS sample buffer for 5 minutes at 75°C and separated by SDS-PAGE. The 
fluorescence signals were detected with a Typhoon Trio imager (GE Healthcare; λex = 
488 nm, λem = 526 nm) before the gels were stained with Coomassie to visualize 
proteins (Supplementary Fig. 1a). To compare de-AMPylation of full-length BiP and 
the isolated substrate binding domain (Fig. 4a) AMP-FAM modified BiPV461F 
(BiPV461F-AMP-FAM) was first cleaved for 4 hours with SubA and then exposed to 0.75 
µM wildtype FICD protein for the indicated periods of time before denaturation and 
SDS-PAGE analysis as described above.  
FP assays were performed in 384 well polysterene microplates (black, flat bottom, 
µCLAER; greiner bio-one) by monitoring fluorescence polarization of FAM (λex = 
485 nm, λem = 535 nm) using a TECAN plate reader (Infinite F500, G-factor ≈ 0.82). 
The reactions were performed in a final sample volume of 30 µl and started by 
addition of either enzyme or substrate. To measure enzyme kinetics at excess of 
substrate the reactions contained the same concentration of enzyme (wildtype FICD 
protein without the GST-tag; [E] = 0.75 µM) and trace amounts of fluorescent 
BiPV461F-AMP-FAM probe (17 nM) and were supplemented with increasing 
concentrations of non-fluorescent BiPV461F-AMP ([S] = 2 µM to 50 µM), assuming that 
both were de-AMPylated with similar efficiency (Fig. 4c). All reactions were 
performed at 30°C in AMPylation buffer. Substrate-only controls were included in 
each experiment for correction of the test sample values. The linear initial rates in 
millipolarization units per second (mP/sec) were converted to reaction velocity 
(µM/sec) using Equation 1, where ΔFP/Δt is the initial rate, ΔFPc is the absolute 
change in FP signal at completion of the reaction, and [S] is the substrate 
concentration.  
 
Equation 1:  ν0= ((ΔFP/Δt)/ΔFPc)*[S] 
 
To calculate the Km for FICD-mediated de-AMPylation of BiPV461F-AMP the 
Michaelis-Menten equation 5 was fitted to a plot of the initial reaction velocities 
against the substrate concentrations from three independent experiments (n = 3). Data 
analysis was performed using Prism 6.0e (GraphPad Software, Inc.). 
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